LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Adapttech Announces £2.25M in Funding
Company News

Adapttech Announces £2.25M in Funding

April 18, 2022 2 min read Premium comments

Advertisement

Secondary#adapttech#insightrange

Birmingham, United Kingdom-based biotechnology startup Adapttech Ltd has recently secured £2.25M in funding from a range of investors, including ACF Investors, Mercia Asset Management, Wealth Club, and Wren Capital. Adapttech has also announced the launch of its INSIGHT Range family of lower-limb prostheses technology.

The company reports that the funding will be allocated toward improving outcomes for patients in need of orthotics and prosthetics. “Adapttech brought its first product to market during 2021, successfully securing a number of sales. We are delighted to be supporting the team with a follow-on investment to continue to scale the business and build out the product portfolio,” said Stephen Windsor, Investment Director at Mercia.

Adapttech is a biomedical technology company that develops tools to benefit patients with physical limitations through empowering their providers with the best clinical tools possible. The company recently entered into licensing agreements with University of Washington for a self-reporting tool called Prosthetic Limb Users Survey of Mobility (PLUS-M), Modus Health for a step-watch software called Stepwatch, and Advanced Rehabilitation Therapy for a tool called Amputee Mobility Predictors (AMPPro/AMPnoPro). These data collection methods will aid in the creation of future, patient-centered products.

The medtech firm is the first to utilize both 3D scanning and dynamic pressure data to create more streamlined and efficient clinical care. The new INSIGHT Range product range features INSIGHT Sense, a portable pressure measurement system that provides real-time data to providers, INSIGHT Digitizer, a prosthetic socket digitizer that provides high-resolution 3D data, and INSIGHT Pro which combines the sophisticated info from the two former tools, for the benefit of larger clinics and facilities.

Adapttech CEO Frederico Carpinteiro stated, “With the new INSIGHT Range, we’re responding to requests for a scanner-less system, reduced hardware costs, and improved data collection. This new funding comes at a time when we are developing exciting new technologies to benefit our O&P clinic customers and their patients. We look forward to continuing our trajectory in growing our revenues, product portfolio, and international business operations.”

Partner at ACF Investors, Paul Fauset, also expressed confidence in the new company’s growth. “The unique IP [intellectual property] at the heart of Adapttech’s products means there is a great opportunity for the company to become a leader in the orthotics and prosthetics industry, with smart technologies that are improving the quality of life for users. This latest round of funding builds on the team’s success and we look forward to seeing the business grow as it accelerates product development.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy